Meds & supplements › Lansoprazole
Medicine · Proton Pump Inhibitor
Lansoprazole delayed-release capsules are a proton pump inhibitor (PPI) indicated for the: Treatment of active duodenal ulcer in adults Eradication of H. pylori to reduce the risk of duodenal ulcer recurrence in adults Maintenance of…
Selected manufacturer label information, organised into consistent sections by Sofidex. Read the full label at DailyMed ↗
Lansoprazole delayed-release capsules are a proton pump inhibitor (PPI) indicated for the: Treatment of active duodenal ulcer in adults Eradication of H. pylori to reduce the risk of duodenal ulcer recurrence in adults Maintenance of healed duodenal ulcers in adults Treatment of active benign gastric ulcer in adults Healing of nonsteroidal anti-inflammatory drugs (NSAID)-associated gastric ulcer in adults Risk reduction of NSAID-associated gastric ulcer in adults Treatment of symptomatic gastroesophageal reflux disease (GERD) in adults and pediatric patients 1 year of age and older.
Treatment of erosive esophagitis (EE) in adults and pediatric patients 1 year of age and older. Maintenance of healing of EE in adults Pathological hypersecretory conditions, including Zollinger-Ellison Syndrome (ZES) in adults 1.1 Treatment of Active Duodenal Ulcer Lansoprazole delayed-release capsules are indicated for short-term treatment (for four weeks) for healing and symptom relief of active duodenal ulcer.
1.2 Eradication of H. pylori to Reduce the Risk of Duodenal Ulcer Recurrence Triple Therapy: lansoprazole/amoxicillin/clarithromycin Lansoprazole delayed-release capsules in combination with amoxicillin plus clarithromycin as triple therapy is indicated for the treatment of patients with H. pylori infection and duodenal ulcer disease (active or one-year history of a duodenal ulcer) to eradicate H. pylori.
Eradication of H. pylori has been shown to reduce the risk of duodenal ulcer recurrence. Please refer to the full prescribing information for amoxicillin and clarithromycin. Dual Therapy: lansoprazole/amoxicillin Lansoprazole delayed-release capsules in combination with amoxicillin as dual therapy is indicated for the treatment of patients with H. pylori infection and duodenal ulcer disease (active or one-year history of a duodenal ulcer) who are either allergic or intolerant to clarithromycin or in whom resistance to clarithromycin is known or suspected (see the clarithromycin prescribing information, MICROBIOLOGY section).
Eradication of H. pylori has been shown to reduce the risk of duodenal ulcer recurrence. Please refer to the full prescribing information for amoxicillin. 1.3 Maintenance of Healed Duodenal Ulcers Lansoprazole delayed-release capsules are indicated in adults to maintain healing of duodenal ulcers. Controlled studies do not extend beyond 12 months.
1.4 Treatment of Active Benign Gastric Ulcer Lansoprazole delayed-release capsules are indicated in adults for short-term treatment (up to eight weeks) for healing and symptom relief of active benign gastric ulcer. 1.5 Healing of NSAID-Associated Gastric Ulcer Lansoprazole delayed-release capsules are indicated in adults for the treatment of NSAID-associated gastric ulcer in patients who continue NSAID use.
Controlled studies did not extend beyond eight weeks. 1.6 Risk Reduction of NSAID-Associated Gastric Ulcer Lansoprazole delayed-release capsules are indicated in adults for reducing the risk of NSAID-associated gastric ulcers in patients with a history of a documented gastric ulcer who require the use of an NSAID. Controlled studies did not extend beyond 12 weeks.
1.7 Treatment of Symptomatic Gastroesophageal Reflux Disease (GERD) Lansoprazole delayed-release capsules are indicated for short-term treatment in adults and pediatric patients 12 years to 17 years of age (up to eight weeks) and pediatric patients one year to 11 years of age (up to 12 weeks) for the treatment of heartburn and other symptoms associated with GERD.
1.8 Treatment of Erosive Esophagitis (EE) Lansoprazole delayed-release capsules are indicated for short-term treatment in adults and pediatric patients 12 years to 17 years of age (up to eight weeks) and pediatric patients one year to 11 years of age (up to 12 weeks) for healing and symptom relief of all grades of EE. For adults who do not heal with lansoprazole for eight weeks (5 to 10%), it may be helpful to give an additional eight weeks of
14-Day Course of Treatment
Repeated 14-Day Courses (if needed)
ask a healthcare professional before use.
Allergy alert:
Symptoms may include:
If an allergic reaction occurs, stop use and seek medical help right away.
In case of overdose, get medical help or contact a Poison Control Center right away (1-800-222-1222).
Lansoprazole USP, 15 mg
sofidex [Internet]. Daloreum; c2026. Lansoprazole; [reviewed 2026 Aug 2; cited 2026 Nov 10]. Available from: https://sofidex.com/patients/medicines/lansoprazole
sofidex. (2026, August 2). Lansoprazole. Daloreum. Retrieved November 10, 2026, from https://sofidex.com/patients/medicines/lansoprazole
Lansoprazole. sofidex. Reviewed August 2, 2026. Accessed November 10, 2026. https://sofidex.com/patients/medicines/lansoprazole
The cited date is today’s, because a citation records when you read the page. The reviewed date is when a clinician last checked it.